Lightstone Ventures related stories
All articles and analysis
NVCA appoints True Ventures' Callaghan as chairmanThe National Venture Capital Association has named Jon Callaghan chairman of its board of directors. A founder and general partner of True Ventures, Callaghan is succeeding Scott Sandell, general partner of New Enterprise Associates. In addition to this appointment, ten new board members were announced at NVCA's annual meeting held in San Francisco. Among them are Mike Carusi, general partner of Lightstone Ventures; Jeff Clavier, founder and managing director of SoftTech VC; Michael Dixon, a partner at Sequoia Capital; and Mary Meeker, a partner at Kleiner Perkins Caufield & Byers.
- Nimbus Therapeutics pulls in $43 mln
Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company's previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.
- ?IPO Profile: Flex Pharma Inc
The drug developer held a $86.4 million IPO
- Flex Pharma raises $40 mln from big investor group
Flex Pharma, a biopharmaceutical company focused on treatments for neuromuscular disorders, has raised $40 million from an investor group. Investors include Longwood Fund, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, Lightstone Ventures, Alexandria Equities, CD-Venture, Bindley Capital Partners, City Hill Ventures and several individuals including Steve Pagliuca, managing director at Bain Capital.
- Santé Ventures leads $18 mln Series B funding in Claret Medical
Santé Ventures has led an $18 million Series B funding round in Claret Medical, a developer of products for cerebral protection during structural heart, vascular and cardiac surgery procedures. Other investors in the funding round included Lightstone Ventures and Easton Capital. James Eadie from Santé Ventures and Hank Plain from Lightstone Ventures will join Claret Medical's board of directors.
European fund briefs for July 2014European opportunities attract Lightstone from the U.S.; life science support in Britain; and Italy’s biggest fund of funds
- Lightstone Ventures closes $172 mln for first fund
Lightstone Ventures said Thursday that it has raised $172 million for its debut life sciences fund. The pool will focus on early-stage biotech and medical device firms.
VCs can pivot, tooVenture firms embark on radical strategic shifts to boost performance, stay funded
- Covidien, Lightstone, NEA back formation of medical device company
Covidien, Lightstone Ventures and New Enterprise Associates will jointly invest in a new company, FIRE1, launched by The Foundry, a medical device incubator. FIRE1, based in Dublin, Ireland, will focus on developing therapeutic devices.
Arboretum branches out to Northeast, West CoastMichigan firm sees opportunity in biotech beyond its Midwest base